Assessing step-therapy programs: A step in the right direction

Journal of Managed Care Pharmacy

Volumn 13, Issue 3, 2007, Pages 273-275

  Gleason, Patrick P ^a,b  

^a Prime Therapeutics LLC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN; PROTON PUMP INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLERGY; ATTENTION DEFICIT DISORDER; BILLING AND CLAIMS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG UTILIZATION; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MANAGED CARE ORGANIZATION; MEDICAL DECISION MAKING; NOTE; PAIN; PHARMACEUTICAL CARE; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PROSPECTIVE PAYMENT; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 34248356441     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.3.273     Document Type: Note

References (6)

1. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther. 2003;25:250-72.
2. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin II receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007; 13(3)235-44.235-44.
3. Gleason PP, Tran T, Tiberg K, West B, Walters C, Lassen D. Angiotensin receptor blocker (ARB) and brand angiotensin-converting enzyme inhibitor (ACEI) step-therapy program outcomes [abstract]. J Manag Care Pharm. 2007;3(2)164-65. Available at: http://www.amcp.org/data/jmcp/ p163-211.pdf. Accessed March 2, 2007.
4. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care. 2004;10:457-64.
5. Dunn JD, Cannon HE, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302. Available at: http://www.amcp.org/data/jmcp/ research_294-302.pdf. Accessed March 2, 2007.
6. Express Scripts, Inc. Drug trend report 2005. Pharmacy benefit guide: 190. Available at: http://www.express-scripts.com/ourcompany/news/ industryreports/drugtrendreport/2005/. Accessed February 26, 2007.